We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regeneron's (REGN) Performance Strong in 2020: What Lies Ahead?
Read MoreHide Full Article
Biotech bigwig Regeneron Pharmaceuticals (REGN - Free Report) delivered a stellar performance in 2020 and is set for a robust show in 2021 on the back of a solid portfolio and a promising pipeline.
The company’s efforts to expand the label of its approved drugs and concurrently develop the pipeline are impressive. While lead drug Eylea’s sales were somewhat affected by the pandemic last year, trends should stabilize this year. Asthma drug, Dupixent, developed in partnership with Sanofi (SNY - Free Report) has posted a strong performance last year and sales are expected to get a boost on continued label expansions of the drug.
Regeneron’s efforts to bring additional products to the market are impressive as well. The FDA approval of Libtayo for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) has diversified the revenue base and the initial uptake of the drug is strong. It is also being developed for the lucrative indication of non-small cell lung cancer (NSCLC). Regeneron is working to expand its label further, which should boost sales.
Share price of the company rallied last year as it is one of the leading pharma/biotech companies along with Eli Lilly (LLY - Free Report) , among others, that are working on antibodies for the treatment of COVID-19. Last month, the company announced encouraging initial data from an ongoing phase I/II/III study of its antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients requiring low-flow oxygen.
Casirivimab and imdevimab is a cocktail of two monoclonal antibodies (also known as REGN10933 and REGN10987, respectively) and was designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19.
We remind investors that the antibody cocktail was granted an Emergency Use Authorization (EUA) by the FDA for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients at least 12 years of age and weighing at least 40 kg, who have received positive results of direct SARS-CoV-2 viral testing and are at high risk for progressing to severe COVID-19 and/or hospitalization.
Regeneron continues to increase in-house production of casirivimab and imdevimab, and has collaborated with Roche (RHHBY - Free Report) to increase the global supply beginning in 2021.
Demand for the antibody cocktail is expected to be strong in the near term, as the pandemic refuses to lose steam and the rollout of the vaccines will take time.
The company has a solid and diverse portfolio, which will reap returns even after the demand for the cocktail subsides.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.4% per year.
These 7 were selected because of their superior potential for immediate breakout.
Image: Bigstock
Regeneron's (REGN) Performance Strong in 2020: What Lies Ahead?
Biotech bigwig Regeneron Pharmaceuticals (REGN - Free Report) delivered a stellar performance in 2020 and is set for a robust show in 2021 on the back of a solid portfolio and a promising pipeline.
The company’s efforts to expand the label of its approved drugs and concurrently develop the pipeline are impressive. While lead drug Eylea’s sales were somewhat affected by the pandemic last year, trends should stabilize this year. Asthma drug, Dupixent, developed in partnership with Sanofi (SNY - Free Report) has posted a strong performance last year and sales are expected to get a boost on continued label expansions of the drug.
Regeneron’s efforts to bring additional products to the market are impressive as well. The FDA approval of Libtayo for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) has diversified the revenue base and the initial uptake of the drug is strong. It is also being developed for the lucrative indication of non-small cell lung cancer (NSCLC). Regeneron is working to expand its label further, which should boost sales.
Share price of the company rallied last year as it is one of the leading pharma/biotech companies along with Eli Lilly (LLY - Free Report) , among others, that are working on antibodies for the treatment of COVID-19. Last month, the company announced encouraging initial data from an ongoing phase I/II/III study of its antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients requiring low-flow oxygen.
Casirivimab and imdevimab is a cocktail of two monoclonal antibodies (also known as REGN10933 and REGN10987, respectively) and was designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19.
We remind investors that the antibody cocktail was granted an Emergency Use Authorization (EUA) by the FDA for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients at least 12 years of age and weighing at least 40 kg, who have received positive results of direct SARS-CoV-2 viral testing and are at high risk for progressing to severe COVID-19 and/or hospitalization.
Regeneron continues to increase in-house production of casirivimab and imdevimab, and has collaborated with Roche (RHHBY - Free Report) to increase the global supply beginning in 2021.
Demand for the antibody cocktail is expected to be strong in the near term, as the pandemic refuses to lose steam and the rollout of the vaccines will take time.
The company has a solid and diverse portfolio, which will reap returns even after the demand for the cocktail subsides.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.4% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>